Health Care

Sanara Medtech insiders’ clustered sell‑offs, including COO Waldrop Jacob’s April 15 tax‑withholding sale, reveal routine portfolio moves but raise questions on short‑term confidence after the FORTIFY launch.

CareDx CEO Hanna John Walter Jr. sells 62,000 shares, sparking debate on management confidence as the company pivots to core transplant‑monitoring and sells a lab division. Explore why insider selling may signal a near‑term valuation correction or r…

Insider selling at Twist Bioscience: CFO’s small April sale reflects routine liquidity, not a red flag, amid strong growth and robust fundamentals.

Insider buying of Travere Therapeutics shares signals management confidence in its rare‑disease pipeline, driving bullish sentiment and potential upside for investors.

Insider buying at ImmuCell signals bullish confidence—Kathy Turner and peers are buying shares as the stock climbs, offering a potential upside for investors.

HRT Financial’s surge in Onconetix shares amid a steep price collapse signals insider confidence—and a potential turnaround—yet investors must weigh biotech risks and pending clinical data before buying.

FMR LLC’s recent modest sell‑off of Structure Therapeutics shares is a routine liquidity move, not a sign of a fundamental shift—focus on the company’s pipeline milestones and insider buying for future upside.

Insider buys reveal Immutep’s confidence: executive stake and 1 m performance‑right shares hint at a possible biotech turnaround.

Insider buying at Travere Therapeutics spikes after FDA approval of FILSPARI, with the Chief Commercial Officer adding 14,000 shares—signaling strong leadership confidence and potential upside for investors.

Whitehawk insider sales: Ball Bryan sold 26,389 shares on April 13 and 92,460 shares on April 14, 2026. The routine RSU‑related sales trim his stake by 14%, but the company’s robust price action and pipeline suggest no immediate downside risk.